|
G2E3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62492241884138E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.55431223447522E-15 |
| Normal-vs-Stage2 |
2.37032615757471E-12 |
| Normal-vs-Stage3 |
1.62458935193399E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
7.116600E-01 |
| Stage1-vs-Stage3 |
1.510030E-01 |
| Stage1-vs-Stage4 |
4.843000E-04 |
| Stage2-vs-Stage3 |
2.004400E-01 |
| Stage2-vs-Stage4 |
5.184100E-03 |
| Stage3-vs-Stage4 |
5.318300E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.22044604925031E-16 |
| Normal-vs-AfricanAmerican |
1.80200000476916E-08 |
| Normal-vs-Asian |
5.55111512312578E-16 |
| Caucasian-vs-AfricanAmerican |
7.411600E-01 |
| Caucasian-vs-Asian |
5.339800E-01 |
| AfricanAmerican-vs-Asian |
5.348800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.11022302462516E-16 |
| Normal-vs-Female |
1.62525548574877E-12 |
| Male-vs-Female |
3.011400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.66533453693773E-15 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(81-100Yrs) |
3.823100E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.405400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.741400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.574200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.161800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.903800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.035000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.033600E-04 |
| Classical-VS-Follicular |
5.368200E-01 |
| Classical-VS-Other |
6.676600E-01 |
| Classical-VS-Normal |
1.28785870856518E-14 |
| Tall-VS-Follicular |
9.843200E-04 |
| Tall-VS-Other |
4.638400E-01 |
| Tall-VS-Normal |
1.62436730732907E-12 |
| Follicular-VS-Other |
5.852600E-01 |
| Follicular-VS-Normal |
1.63857816204427E-12 |
| Other-VS-Normal |
1.778780E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.66133814775094E-16 |
| Normal-vs-N1 |
1.62447832963153E-12 |
| N0-vs-N1 |
1.775790E-01 |
|
|
